Tislelizumab Combined Treatment in Refractory Extranodal NK/T-cell Lymphoma

Inclusion Criteria

• •1. Patients with biopsy histopathology, immunohistochemistry and EBER test meet ing the WHO 2016 diagnostic criteria for NK/T cell lymphoma.
• •2. With progressive disease after asparaginase-based combined chemotherapy
• •3. Have experienced multiple courses of PD-1/PD-L1 treatment with non-responsive or progressive disease.
• •4. PET/CT or CT/MRI with at least one measurable lesion or objectively evaluable lesion.
• •5. General ECOG score 0-3 points.
• •6. The laboratory examination within 1 week before enrollment meets the following conditions:
• •Blood routine: Hb\>80g/L, PLT\>50×109/L. Liver function: ALT, AST, TBIL ≤ 2 times the upper limit of normal. Renal function: Cr is normal. Blood coagulation test: plasma fibrinogen ≥1.0g/L. Heart function: LVEF≥50%, ECG did not indicate any acute myocardial infarction, arrhythmia, or atrioventricular block of degree I or more.
• •7. Signed informed consent form.
• •8. Voluntarily comply with research protocols, follow-up plans, laboratory and auxiliary examinations.